Thank you.
There are approximately 180 submissions that were in backlog when we started at the beginning of this year. We have addressed that backlog by targeting greater than 90% of that backlog. The backlog is basically saying that if a submission is beyond our published time under our management of regulatory submissions, which is, say, 300 days for a new drug submission, it would be considered backlog if it were at 301 days.
We have addressed over 90% of that this year, meaning that this year—right now, as we speak today—there are approximately 50 submissions that we would consider to be in backlog right now. So we've made a significant difference between that and this year.
By the time we finish the fiscal year this year, towards the end of 2008 or the beginning of 2009, those 50 submissions as well as any new submissions coming in will be picked up and be reviewed on time, meaning that by fiscal year 2009 we'll be in a position such that all submissions will be reviewed within our management of regulatory submission timeframes.